Your browser doesn't support javascript.
loading
Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19.
Povysil, Gundula; Butler-Laporte, Guillaume; Shang, Ning; Wang, Chen; Khan, Atlas; Alaamery, Manal; Nakanishi, Tomoko; Zhou, Sirui; Forgetta, Vincenzo; Eveleigh, Robert Jm; Bourgey, Mathieu; Aziz, Naveed; Jones, Steven Jm; Knoppers, Bartha; Scherer, Stephen W; Strug, Lisa J; Lepage, Pierre; Ragoussis, Jiannis; Bourque, Guillaume; Alghamdi, Jahad; Aljawini, Nora; Albes, Nour; Al-Afghani, Hani M; Alghamdi, Bader; Almutairi, Mansour S; Mahmoud, Ebrahim Sabri; Abu-Safieh, Leen; El Bardisy, Hadeel; Harthi, Fawz S Al; Alshareef, Abdulraheem; Suliman, Bandar Ali; Alqahtani, Saleh A; Almalik, Abdulaziz; Alrashed, May M; Massadeh, Salam; Mooser, Vincent; Lathrop, Mark; Fawzy, Mohamed; Arabi, Yaseen M; Mbarek, Hamdi; Saad, Chadi; Al-Muftah, Wadha; Jung, Junghyun; Mangul, Serghei; Badji, Radja; Thani, Asma Al; Ismail, Said I; Gharavi, Ali G; Abedalthagafi, Malak S; Richards, J Brent.
Afiliação
  • Povysil G; Institute for Genomic Medicine, Columbia University, New York, New York, USA.
  • Butler-Laporte G; Lady Davis Institute for Medical Research, Montréal, Québec, Canada.
  • Shang N; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada.
  • Wang C; Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
  • Khan A; Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
  • Alaamery M; Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.
  • Nakanishi T; Developmental Medicine Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
  • Zhou S; Saudi Human Genome Project at King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Forgetta V; Lady Davis Institute for Medical Research, Montréal, Québec, Canada.
  • Eveleigh RJ; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Bourgey M; Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Aziz N; Lady Davis Institute for Medical Research, Montréal, Québec, Canada.
  • Jones SJ; Lady Davis Institute for Medical Research, Montréal, Québec, Canada.
  • Knoppers B; Canadian Centre for Computational Genomics, McGill University, Montréal, Québec, Canada.
  • Scherer SW; McGill Genome Center, McGill University, Montréal, Québec, Canada.
  • Strug LJ; Canadian Centre for Computational Genomics, McGill University, Montréal, Québec, Canada.
  • Lepage P; McGill Genome Center, McGill University, Montréal, Québec, Canada.
  • Ragoussis J; Canadian COVID Genomics Network, HostSeq Project, Canada.
  • Bourque G; Canadian COVID Genomics Network, HostSeq Project, Canada.
  • Alghamdi J; Canadian COVID Genomics Network, HostSeq Project, Canada.
  • Aljawini N; Canadian COVID Genomics Network, HostSeq Project, Canada.
  • Albes N; Canadian COVID Genomics Network, HostSeq Project, Canada.
  • Al-Afghani HM; Canadian Centre for Computational Genomics, McGill University, Montréal, Québec, Canada.
  • Alghamdi B; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Almutairi MS; Canadian Centre for Computational Genomics, McGill University, Montréal, Québec, Canada.
  • Mahmoud ES; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Abu-Safieh L; McGill Genome Center, McGill University, Montréal, Québec, Canada.
  • El Bardisy H; Canadian Centre for Computational Genomics, McGill University, Montréal, Québec, Canada.
  • Alshareef A; KACST-BWH Centre of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Suliman BA; KACST-BWH Centre of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Alqahtani SA; Laboratory Department, Security Forces Hospital, General Directorate of Medical Services, Ministry of Interior, Makkah, Saudi Arabia.
  • Almalik A; Developmental Medicine Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
  • Alrashed MM; Developmental Medicine Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
  • Massadeh S; Ministry of the National Guard Health Affairs, King Abdullah International Medical Research Center and King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • Mooser V; Genomics Research Department, Saudi Human Genome Project, King Fahad Medical City and King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Lathrop M; Genomics Research Department, Saudi Human Genome Project, King Fahad Medical City and King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Fawzy M; Genomics Research Department, Saudi Human Genome Project, King Fahad Medical City and King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Arabi YM; College of Applied Medical Sciences, Taibah University, Madina, Saudi Arabia.
  • Mbarek H; College of Applied Medical Sciences, Taibah University, Madina, Saudi Arabia.
  • Saad C; Liver Transplant Unit, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
  • Al-Muftah W; Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Jung J; Life Science and Environmental Institute, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Mangul S; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
  • Badji R; Developmental Medicine Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
  • Thani AA; Saudi Human Genome Project at King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.
  • Ismail SI; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Gharavi AG; Department of Human Genetics, McGill University, Montréal, Québec, Canada.
  • Abedalthagafi MS; Canadian COVID Genomics Network, HostSeq Project, Canada.
  • Richards JB; Canadian Centre for Computational Genomics, McGill University, Montréal, Québec, Canada.
J Clin Invest ; 131(14)2021 07 15.
Article em En | MEDLINE | ID: mdl-34043590
A recent report found that rare predicted loss-of-function (pLOF) variants across 13 candidate genes in TLR3- and IRF7-dependent type I IFN pathways explain up to 3.5% of severe COVID-19 cases. We performed whole-exome or whole-genome sequencing of 1,864 COVID-19 cases (713 with severe and 1,151 with mild disease) and 15,033 ancestry-matched population controls across 4 independent COVID-19 biobanks. We tested whether rare pLOF variants in these 13 genes were associated with severe COVID-19. We identified only 1 rare pLOF mutation across these genes among 713 cases with severe COVID-19 and observed no enrichment of pLOFs in severe cases compared to population controls or mild COVID-19 cases. We found no evidence of association of rare LOF variants in the 13 candidate genes with severe COVID-19 outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Mutação com Perda de Função / SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Clin Invest Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon Tipo I / Mutação com Perda de Função / SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Clin Invest Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos